Evidence map›Paper›PMID 34260589›Full record

ArticlePLoS computational biology2021

COVIDomic: A multi-modal cloud-based platform for identification of risk factors associated with COVID-19 severity.

Vladimir Naumov, Eugene Lane, Stefan Pushkov, Ekaterina Kozlova, Konstantin Romantsov, Alexander Kalashnikov, Fedor Galkin, Nina Tihonova, Anastasia Shneyderman, Egor Galkin and 13 more

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Classifying COVID-19 based on amino acids encoding with machine learning algorithms.Chemometrics and intelligent laboratory systems : an international journal sponsored by the Chemometrics Society · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 5 countries.

Vladimir NaumovInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.ORCID 0000-0003-3863-4925
Eugene LaneInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.ORCID 0000-0002-3012-9708
Stefan PushkovInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.ORCID 0000-0002-1768-394X
Ekaterina KozlovaInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.ORCID 0000-0003-2737-3694
Konstantin RomantsovInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.ORCID 0000-0003-0731-8575
Alexander KalashnikovInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
Fedor GalkinInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.ORCID 0000-0002-5709-9529
Nina TihonovaInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
Anastasia ShneydermanInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
Egor GalkinInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.ORCID 0000-0001-9636-5706
Arsenii ZinkevichInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
Stephanie M CopeIntel Corporation, Santa Clara, California, United States of America.
Ramanathan SethuramanIntel Corporation, Bangalore India.
Tudor I OpreaDepartment of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, United States of America.ORCID 0000-0002-6195-6976
Alexander T PearsonDepartment of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, Ilinois, United States of America.ORCID 0000-0003-2801-7456
Savas TayPritzker School of Molecular Engineering, University of Chicago, Chicago, Ilinois, United States of America.ORCID 0000-0002-1912-6020
Nishant AgrawalDepartment of Surgery, Section of Otolaryngology-Head and Neck Surgery, University of Chicago, Chicago, Ilinois, United States of America.
Alexey DubovenkoInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.ORCID 0000-0002-8424-5106
Quentin VanhaelenInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.ORCID 0000-0002-4611-2046
Ivan OzerovInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
Alex AliperInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.ORCID 0000-0002-4363-0710
Evgeny IzumchenkoDepartment of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, Ilinois, United States of America.
Alex ZhavoronkovInsilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.ORCID 0000-0001-7067-8966
University of Chicago · USIntel (India) · INIntel (United States) · USLomonosov Moscow State University · RUUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in December 2019 in Wuhan, China. It was quickly established that both the symptoms and the disease severity may vary from one case to another and several strains of SARS-CoV-2 have been identified. To gain a better understanding of the wide variety of SARS-CoV-2 strains and their associated symptoms, thousands of SARS-CoV-2 genomes have been sequenced in dozens of countries. In this article, we introduce COVIDomic, a multi-omics online platform designed to facilitate the analysis and interpretation of the large amount of health data collected from patients with COVID-19. The COVIDomic platform provides a comprehensive set of bioinformatic tools for the multi-modal metatranscriptomic data analysis of COVID-19 patients to determine the origin of the coronavirus strain and the expected severity of the disease. An integrative analytical workflow, which includes microbial pathogens community analysis, COVID-19 genetic epidemiology and patient stratification, allows to analyze the presence of the most common microbial organisms, their antibiotic resistance, the severity of the infection and the set of the most probable geographical locations from which the studied strain could have originated. The online platform integrates a user friendly interface which allows easy visualization of the results. We envision this tool will not only have immediate implications for management of the ongoing COVID-19 pandemic, but will also improve our readiness to respond to other infectious outbreaks.

Indexed as

Cloud ComputingUser-Computer InterfaceComputational BiologyCOVID-19HumansRisk FactorsSARS-CoV-2Severity of Illness Index

Identifiers

PMID34260589
PMCPMC8312936
OpenAlexW3179278515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.